Clioquinol inhibits NGF-induced Trk autophosphorylation and neurite outgrowth in PC12 cells

Brain Research

Volumn 1301, Issue , 2009, Pages 110-115

  Asakura, Kunihiko ^a   Ueda, Akihiro ^a   Kawamura, Naoki ^a   Ueda, Madoka ^a   Mihara, Takateru ^a   Mutoh, Tatsuro ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Clioquinol; Nerve growth factor; SMON; Tyrosine phosphorylation

Indexed keywords

CLIOQUINOL; MITOGEN ACTIVATED PROTEIN KINASE; NERVE GROWTH FACTOR; TYROSINE KINASE RECEPTOR;

ANIMAL CELL; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; NERVE CELL; NERVE CELL DIFFERENTIATION; NERVE FIBER GROWTH; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL COUNT; CELL SHAPE; CELL SURVIVAL; CELLS, CULTURED; CLIOQUINOL; DOSE-RESPONSE RELATIONSHIP, DRUG; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; NERVE GROWTH FACTOR; NEURITES; NEUROFILAMENT PROTEINS; NEUROTOXINS; PC12 CELLS; PHOSPHORYLATION; RATS; RECEPTOR, TRKA; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 71849099656     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.09.011     Document Type: Article

References (20)

1. Arbiser J.L., Kraeft S.-K., van Leeuwen R., Hurwitz S.J., Selig M., Dickersin G.R., Flint A., Byers H.R., and Chen L.B. Clioquinol-zinc chelate: a candidate causative agent of subacute myelo-optic neuropathy. Mol. Med. 4 (1998) 665-670
2. Asakura K., Murayama H., Himeda T., and Ohara Y. Expression of L* protein of Theiler's murine encephalomyelitis virus in the chronic phase of infection. J. Gen. Virol. 88 (2007) 2268-2274
3. Chen D., Cui Q.C., Yang H., Barrea R.A., Sarkar F.H., Sheng S., Yan B., Reddy P.V., and Ping Dou Q. Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and anti-tumor activities in human prostate cancer cells and xenografts. Cancer Res. 67 (2007) 1636-1644
4. Cherny R., Atwood C., Xilinas M., Gray D., Jones W., McLean C., Barnham K., Volitakis I., Fraser F., Kim Y., Huang X., Goldstein L., Moir R., Lim J., Beyreuther K., Zheng H., Tanzi R., Masters C., and Bush A. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30 (2001) 665-676
5. Ismail T., Mauerhofer E., and Slomianka L. The hippocampal region of rates and mice after a single i.p. dose of clioquinol: loss of synaptic zinc, cell death and c-Fos induction. Neuroscience 157 (2008) 697-707
6. Kaplan D.R., and Miller F.D. Neurotrophin signal transduction in the nervous system. Curr. Opin. Neurobiol. 10 (2000) 381-391
7. Konagaya M., Matsumoto A., Takase S., Mizutani T., Sobue G., Konishi T., Hayabara T., Iwashita H., Ujihira T., Miyata K., and Matsuoka Y. Clinical analysis of longstanding subacute myelo-optico-neuropathy: sequelae of clioquinol at 32 years after its ban. J. Neurol. Sci. 218 (2004) 85-90
8. Matsuki Y., Yoshimura S., and Abe M. SMON and pharmacokinetics of chinoform with special reference to animal species difference. Yakugaku Zasshi 7 (1997) 936-956 [in Japanese with English abstract]
9. Mutoh T., Tokuda A., Miyadai T., Hamaguchi M., and Fujiki N. Ganglioside GM1 binds to the Trk protein and regulates receptor function. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 5087-5091
10. Mutoh T., Hamano T., Tokuda A., and Kuriyama M. Unglycosylated Trk protein does not co-localized nor associate with ganglioside GM1 in stable clone of PC12 cells overexpressing Trk (PCtrk cells). Glycoconj. J. 17 (2000) 233-237
11. Nakae K., Yamamoto S., Shigematsu I., and Kono R. Relation between subacute myelo-optic neuropathy (S.M.O.N.) and clioquinol: nationwide survey. Lancet 1 (1973) 171-173
12. Nguyen T., Hamby A., and Massa S.M. Clioquinol down-regulates mutant huntintin expression in vitro and mitigates pathology in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 11840-11845
13. Ohtsuka K., Ohishi N., Eguchi G., and Yagi K. Degeneration of retinal neuroblasts by chinoform-ferric chelate. Experientia 38 (1982) 120-122
14. Ritchie C.W., Bush A.I., Mackinnon A., Macfarlane S., Mastwyk M., MacGregor L., Kiers L., Cherny R., Li Q.X., Tammer A., Carrington D., Mavros C., Volitakis I., Xilinas M., Ames D., Davis S., Beyreuther K., Tanzi R.E., and Masters C.L. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch. Neurol. 60 (2003) 1685-1691
15. Ross G.M., Shamovsky I.L., Lawrance G., Solc M., Dostaler S.M., Jimmo S.L., Weaver D.F., and Riopelle R.J. Zinc alters conformation and inhibits biological activities of nerve growth factor and related neurotrophins. Nat. Med. 3 (1997) 872-878
16. Tateishi J. Subacute myelo-optico-neuropathy: clioquinol intoxication in humans and animals. Neuropathology 20 (2000) S20-S24
17. Thoenen H. Neurotrophins and neuronal plasticity. Science 270 (1995) 593-598
18. Tsubaki T., Honma Y., and Hoshi M. Neurological syndrome associated with clioquinol. Lancet 1 (1971) 696-697
19. Yagi K., Ohtsuka K., and Ohishi N. Lipid peroxidation caused by chinoform-ferric chelate in cultured neural retinal cells. Experientia 4 (1985) 1561-1563
20. Yassin M.S., Ekblom J., Xilinas M., Gottfries C.G., and Oreland L. Changes in uptake of vitamin B12 and trace minerals in brains of mice treated with clioquinol. J. Neurol. Sci. 173 (2000) 40-44